Prabhudas Lilladher is bullish on Krishna Institute of Medical Sciences has recommended buy rating on the stock with a target price of Rs 2000 in its research report dated August 09, 2023.

Read More

​ Prabhudas Lilladher is bullish on Krishna Institute of Medical Sciences has recommended buy rating on the stock with a target price of Rs 2000 in its research report dated August 09, 2023. Prabhudas Lilladher is bullish on Krishna Institute of Medical Sciences has recommended buy rating on the stock with a target price of Rs 2000 in its research report dated August 09, 2023.  Moneycontrol Latest News Read More  

Prabhudas Lilladher is bullish on Krishna Institute of Medical Sciences has recommended buy rating on the stock with a target price of Rs 2000 in its research report dated August 09, 2023.

Prabhudas Lilladher is bullish on Max Healthcare Institute has recommended buy rating on the stock with a target price of Rs 610 in its research report dated August 09, 2023.

Read More

​ Prabhudas Lilladher is bullish on Max Healthcare Institute has recommended buy rating on the stock with a target price of Rs 610 in its research report dated August 09, 2023. Prabhudas Lilladher is bullish on Max Healthcare Institute has recommended buy rating on the stock with a target price of Rs 610 in its research report dated August 09, 2023.  Moneycontrol Latest News Read More  

Prabhudas Lilladher is bullish on Max Healthcare Institute has recommended buy rating on the stock with a target price of Rs 610 in its research report dated August 09, 2023.

Prabhudas Lilladher is bullish on J.B. Chemicals and Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 3000 in its research report dated August 10, 2023.

Read More

​ Prabhudas Lilladher is bullish on J.B. Chemicals and Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 3000 in its research report dated August 10, 2023. Prabhudas Lilladher is bullish on J.B. Chemicals and Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 3000 in its research report dated August 10, 2023.  Moneycontrol Latest News Read More  

Prabhudas Lilladher is bullish on J.B. Chemicals and Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 3000 in its research report dated August 10, 2023.

Lucrative periods like the August 15 holiday will help the India box office make up for the shortfall in the first half of 2023, said an analyst.

Read More

​ Lucrative periods like the August 15 holiday will help the India box office make up for the shortfall in the first half of 2023, said an analyst. Lucrative periods like the August 15 holiday will help the India box office make up for the shortfall in the first half of 2023, said an analyst.  Moneycontrol Latest News Read More  

Lucrative periods like the August 15 holiday will help the India box office make up for the shortfall in the first half of 2023, said an analyst.

Sales from the formulation business in India in Q1 was at Rs 1,064.3 crore over Rs 1,035.2 crore in the previous corresponding quarter, a growth of 2.8 per cent, the company said, adding, in North America, sales of finished dosage formulations clocked Rs 808.5 crore as against Rs 662.8 crore in the same period a year ago.

Read More

​ Sales from the formulation business in India in Q1 was at Rs 1,064.3 crore over Rs 1,035.2 crore in the previous corresponding quarter, a growth of 2.8 per cent, the company said, adding, in North America, sales of finished dosage formulations clocked Rs 808.5 crore as against Rs 662.8 crore in the same period a year ago. Sales from the formulation business in India in Q1 was at Rs 1,064.3 crore over Rs 1,035.2 crore in the previous corresponding quarter, a growth of 2.8 per cent, the company said, adding, in North America, sales of finished dosage formulations clocked Rs 808.5 crore as against Rs 662.8 crore in the same period a year ago.  Moneycontrol Latest News Read More  

Sales from the formulation business in India in Q1 was at Rs 1,064.3 crore over Rs 1,035.2 crore in the previous corresponding quarter, a growth of 2.8 per cent, the company said, adding, in North America, sales of finished dosage formulations clocked Rs 808.5 crore as against Rs 662.8 crore in the same period a year ago.

This subsidiary will focus on lending business operations, strengthening the company’s foothold in the lending segment. Abans Holdings is looking to become a dominant player in alternative investments.

Read More

​ This subsidiary will focus on lending business operations, strengthening the company’s foothold in the lending segment. Abans Holdings is looking to become a dominant player in alternative investments. This subsidiary will focus on lending business operations, strengthening the company’s foothold in the lending segment. Abans Holdings is looking to become a dominant player in alternative investments.  Moneycontrol Latest News Read More  

This subsidiary will focus on lending business operations, strengthening the company’s foothold in the lending segment. Abans Holdings is looking to become a dominant player in alternative investments.

Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe.

Read More

​ Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe. Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe.  Moneycontrol Latest News Read More  

Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe.

Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe.

Read More

​ Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe. Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe.  Moneycontrol Latest News Read More  

Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe.

Net profit of the oil and gas explorer came in at Rs 17,383 crore in Q1, compared to Rs 8,581 crore in the year-ago period.

Read More

​ Net profit of the oil and gas explorer came in at Rs 17,383 crore in Q1, compared to Rs 8,581 crore in the year-ago period. Net profit of the oil and gas explorer came in at Rs 17,383 crore in Q1, compared to Rs 8,581 crore in the year-ago period.  Moneycontrol Latest News Read More  

Net profit of the oil and gas explorer came in at Rs 17,383 crore in Q1, compared to Rs 8,581 crore in the year-ago period.

Incorporated in 1986, Patanjali Foods (formerly known as Ruchi Soya Industries Ltd) is one of the leading firms in the edible oils segment and is aiming to become a major player in FMCG and FMHG as well.

Read More

​ Incorporated in 1986, Patanjali Foods (formerly known as Ruchi Soya Industries Ltd) is one of the leading firms in the edible oils segment and is aiming to become a major player in FMCG and FMHG as well. Incorporated in 1986, Patanjali Foods (formerly known as Ruchi Soya Industries Ltd) is one of the leading firms in the edible oils segment and is aiming to become a major player in FMCG and FMHG as well.  Moneycontrol Latest News Read More  

Incorporated in 1986, Patanjali Foods (formerly known as Ruchi Soya Industries Ltd) is one of the leading firms in the edible oils segment and is aiming to become a major player in FMCG and FMHG as well.